MetaCap

Evommune (EVMN) vs Galectin Therapeutics (GALT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Galectin Therapeutics (GALT) has outperformed Evommune (EVMN) over the past year, losing 49.7% versus a loss of 62.4%. Evommune is the larger company by market cap ($291.1 million vs $271.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVMN-62.37%GALT-49.72%
+76%-2%-80%
Nov 21, 20251 yearNov 20, 2026
EVMN-61.76%GALT-48.27%
+79%-0%-79%
Nov 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVMN versus GALT key metrics
MetricEVMNGALT
Share price$7.04$2.69
Market cap$291.10M$271.35M
1-day change-2.76%-4.27%
YTD return-58.88%-35.34%
1-year return-62.37%-49.72%
5-year return—+4.67%
EPS (TTM)$-3.83$-0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.00M—
Revenue growth (YoY)+85.71%—
Net income (latest FY)$-68.87M$-30.84M
Operating margin-623.62%—
Net margin-529.77%—
52-week high$33.20$7.13
52-week low$4.94$2.03
Distance from 52-week high-78.80%-62.27%
Analyst consensusbuystrong_buy
Avg. price target upside+210.94%+308.92%
Average volume841.65K252.31K
Shares outstanding41.35M100.88M
Employees489
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GALT has outperformed EVMN by 12.7 percentage points over the past year.

About Evommune

EVMN stock →

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

EVMN vs GALT FAQ

Which is bigger, Evommune or Galectin Therapeutics?

Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $271.35M for Galectin Therapeutics (GALT).

Which stock has performed better over the past year, EVMN or GALT?

GALT returned -49.72% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.

Are Evommune and Galectin Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons